New therapeutic modalities are challenging the biopharma industry as never before. The curative impact of first-wave chimeric antigen receptor (CAR)-T cell therapies in blood cancers, for example, has spurred dozens of companies to launch hundreds of clinical trials for next-generation advanced therapies.
However, a digital sea change is needed if we are to rapidly master the unique complexities for producing cell therapies at scale. Ori Biotech’s Chief Digital Officer Kevin Gordon discusses the key pain points that are preventing patients from accessing this new generation of curative therapies.